Pulse nav.journalClub Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

April 10, 2026

Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children

Puntos clave

The aim is to evaluate the effectiveness of tocilizumab in treating severe CNS inflammatory presentations in children.
Class IV evidence study design
Assessment of clinical outcomes
Population involved children with acute-severe CNS inflammation
Tocilizumab improved clinical outcomes for children with severe CNS inflammation.
The findings suggest a positive therapeutic effect of tocilizumab on acute severe events.

Resumen

This study provides Class IV evidence that TCZ improves clinical outcomes in children with acute-severe CNS inflammatory events.

Me gusta

Guardar

Compartir

Me gusta

Guardar

Compartir

Cite This Study

Marefi et al. (Tue,) studied this question.

synapsesocial.com/papers/69d894526c1944d70ce0547b https://doi.org/https://doi.org/10.1212/wnl.0000000000214926

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The role of early immunotherapy in rasmussen’s encephalitis2026 · 2 citations
2Life-Threatening MOG Antibody-Associated Hemorrhagic ADEM With Elevated CSF IL-62024 · 20 citations
3A case report and literature review on tocilizumab-cured acute necrotizing encephalopathy caused by influenza A virus2024 · 12 citations
4Tocilizumab (Actemra)2017 · 328 citations
5Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder2019 · 638 citations

Rol del Tocilizumab en Presentaciones Inflamatorias Severas del SNC en Niños | Synapse